ARQL Share Price

Open 1.39 Change Price %
High 1.41 1 Day -0.01 -0.75
Low 1.32 1 Week -0.04 -2.92
Close 1.33 1 Month -0.05 -3.62
Volume 108504 1 Year -0.79 -37.26
52 Week High 2.30
52 Week Low 0.00
ARQL Important Levels
Resistance 2 1.41
Resistance 1 1.38
Pivot 1.35
Support 1 1.28
Support 2 1.25
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

ArQule, Inc. (NASDAQ: ARQL)

ARQL Technical Analysis 5
As on 9th Dec 2016 ARQL Share Price closed @ 1.33 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.62 & Strong Sell for SHORT-TERM with Stoploss of 1.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
ARQL Target for December
1st Target up-side 1.55
2nd Target up-side 1.68
3rd Target up-side 1.8
1st Target down-side 1.19
2nd Target down-side 1.06
3rd Target down-side 0.94
ARQL Other Details
Segment EQ
Market Capital 153362256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.arqule.com
ARQL Address
ARQL
19 Presidential Way
Woburn, MA 01801
United States
Phone: 781-994-0300
Fax: 781-376-6019
Interactive Technical Analysis Chart ArQule, Inc. ( ARQL NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ArQule, Inc.
ARQL Business Profile
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase (c-Met). C-Met is a target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. It focuses on the clinical programs based upon data that is continually generated. Its indications include non-small cell lung cancer (NSCLC), liver cancer (hepatocellular carcinoma or HCC) and colorectal cancer. In January 2011, the Company enrolled the first patient in the Phase III MARQUEE (Met inhibitor ARQ 197 plus Erlotinib vs. Erlotinib plus placebo in NSCLC) trial of tivantinib in NSCLC in combination with erlotinib, an approved anti-cancer agent. In August 2011, Kyowa Hakko Kirin announced the initiation of the Phase III ATTENTION (Asian Trial of Tivantinib plus Erlotinib vs. Erlotinib for NSCLC without EGFR Mutation) trial of tivantinib in combination with erlotinib. The Company and its partners, Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) and Kyowa Hakko Kirin Co., Ltd., (Kyowa Hakko Kirin) are implementing a clinical development program designed to realize the broad potential of ARQ 197 as a well tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications. These include non-small cell lung cancer (NSCLC), liver cancer, colorectal cancer, germ cell tumors and gastric cancer. Its pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The candidates in this pipeline are ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, both of which are in Phase 1 clinical testing. A third pipeline program, focused on small molecule inhibitors of fibroblast growth factor receptor, is in pre-clinical development.